What’s Next PanOptica? We Ask CEO Chaney

10/11/17 • 30 min

OIS Podcast | Ophthalmology's leading Podcast

CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specialty truly is. Chaney also explains why PanOptica’s pursuit of an eye-drop-based treatment for AMD and DR is personal.

Previous Episode

ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor

With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. Rahhal, MD, says the firm is planning to raise a much larger fund that could elevate its standing as a seed-stage investor in ophthalmology companies.

Next Episode

Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease

Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemini hopes to advance the war against these dreadful diseases.